216 related articles for article (PubMed ID: 24670875)
21. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
[TBL] [Abstract][Full Text] [Related]
22. Regulation of dual specificity phosphatases in breast cancer during initial treatment with Herceptin: a Boolean model analysis.
Buiga P; Elson A; Tabernero L; Schwartz JM
BMC Syst Biol; 2018 Apr; 12(Suppl 1):11. PubMed ID: 29671404
[TBL] [Abstract][Full Text] [Related]
23. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castillo B; Cufí S; Del Barco S; Lopez-Bonet E; Brunet J; Menendez JA
Biochem Biophys Res Commun; 2010 Jun; 397(1):27-33. PubMed ID: 20470755
[TBL] [Abstract][Full Text] [Related]
24. V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.
von Schwarzenberg K; Lajtos T; Simon L; Müller R; Vereb G; Vollmar AM
Mol Oncol; 2014 Feb; 8(1):9-19. PubMed ID: 24055142
[TBL] [Abstract][Full Text] [Related]
25. Modelling the role of dual specificity phosphatases in herceptin resistant breast cancer cell lines.
Buiga P; Elson A; Tabernero L; Schwartz JM
Comput Biol Chem; 2019 Jun; 80():138-146. PubMed ID: 30952040
[TBL] [Abstract][Full Text] [Related]
26. mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer.
von der Heyde S; Wagner S; Czerny A; Nietert M; Ludewig F; Salinas-Riester G; Arlt D; Beißbarth T
PLoS One; 2015; 10(2):e0117818. PubMed ID: 25710561
[TBL] [Abstract][Full Text] [Related]
27. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines.
Kauraniemi P; Hautaniemi S; Autio R; Astola J; Monni O; Elkahloun A; Kallioniemi A
Oncogene; 2004 Jan; 23(4):1010-3. PubMed ID: 14647448
[TBL] [Abstract][Full Text] [Related]
28. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
29. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
[TBL] [Abstract][Full Text] [Related]
30. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D
Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457
[TBL] [Abstract][Full Text] [Related]
31. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
Gijsen M; King P; Perera T; Parker PJ; Harris AL; Larijani B; Kong A
PLoS Biol; 2010 Dec; 8(12):e1000563. PubMed ID: 21203579
[TBL] [Abstract][Full Text] [Related]
32. The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Cuyàs E; López-Bonet E; Martin-Castillo B; Joven J; Menendez JA
Sci Rep; 2013; 3():2469. PubMed ID: 23965851
[TBL] [Abstract][Full Text] [Related]
33. [Trastuzumab (herceptin) for the medical treatment of breast cancer].
Bayoudh L; Afrit M; Daldoul O; Zarrad M; Boussen H
Tunis Med; 2012 Jan; 90(1):6-12. PubMed ID: 22311450
[TBL] [Abstract][Full Text] [Related]
34. Development of Herceptin resistance in breast cancer cells.
Kute T; Lack CM; Willingham M; Bishwokama B; Williams H; Barrett K; Mitchell T; Vaughn JP
Cytometry A; 2004 Feb; 57(2):86-93. PubMed ID: 14750129
[TBL] [Abstract][Full Text] [Related]
35. Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.
DI Cara G; Marengo G; Albanese NN; Marabeti MR; Musso R; Cancemi P; Pucci-Minafra I
Anticancer Res; 2013 Feb; 33(2):489-503. PubMed ID: 23393341
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab (herceptin).
Gemmete JJ; Mukherji SK
AJNR Am J Neuroradiol; 2011 Sep; 32(8):1373-4. PubMed ID: 21816914
[TBL] [Abstract][Full Text] [Related]
37. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
Joshi JP; Brown NE; Griner SE; Nahta R
Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025
[TBL] [Abstract][Full Text] [Related]
38. Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers.
Boyer AP; Collier TS; Vidavsky I; Bose R
Mol Cell Proteomics; 2013 Jan; 12(1):180-93. PubMed ID: 23105007
[TBL] [Abstract][Full Text] [Related]
39. Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.
Hubalek M; Brunner C; Matthä K; Marth C
Wien Med Wochenschr; 2010 Nov; 160(19-20):506-12. PubMed ID: 20972709
[TBL] [Abstract][Full Text] [Related]
40. Application of 19F magnetic resonance to study the efficacy of fluorine labeled drugs in the three-dimensional cultured breast cancer cells.
Bartusik D; Tomanek B
Arch Biochem Biophys; 2010 Jan; 493(2):234-41. PubMed ID: 19900396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
